Regeneron recently announced it would initiate a quarterly dividend of $0.88, a competitive amount for a company first ...

Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for ...

While Bayer’s consumer and crop science divisions continued to slide—both in the fourth quarter and in 2024 overall—the ...

It has been about a month since the last earnings report for Regeneron (REGN). Shares have lost about 4.1% in that time frame, underperforming the S&P 500. Will the recent negative trend continue ...

Bayer HealthCare's Eylea (aflibercept solution for injection into the eye) has been approved by the European Commission for the treatment of visual impairment due to diabetic macular oedema (DMO).

Bayer AG BAYRY reported fourth-quarter 2024 core earnings of 28 cents per American Depositary Receipt (ADR), in line with the ...

Bayer has submitted an application to the European Medicines Agency (EMA) to expand treatment intervals of up to 6 months with Eylea 8 mg (aflibercept 8 mg, 114.3 mg/ml solution for injection) for the ...

Please note that Regeneron co-developed Eylea with the HealthCare unit of Bayer AG BAYRY. Regeneron records net product sales of Eylea in the United States and Bayer does the same outside the country.

Eylea HD is developed by Regeneron in partnership with Bayer. The QUASAR trial is being conducted by Bayer as part of its collaboration agreement with Regeneron. Regeneron holds exclusive rights ...

"We are extremely pleased with this new step in the development of our biosimilar candidate to Eylea ®, as better access will benefit patients and their caregivers," said Joseph McClellan ...

Bayer earns license revenues from JNJ for Xarelto sales in the United States. Sales of the ophthalmology drug, Eylea, increased 0.9% to €833 million, driven by higher volumes and prices.